SIC
INDV icon

SJS Investment Consulting’s Indivior Pharmaceuticals INDV Stock Holding History

SJS Investment Consulting’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.13K Buy
52
+47
+940% +$1.71K ﹤0.01% 1753
2026
Q1 		$153 Sell
5
-33
-87% -$1.09K ﹤0.01% 2043
2025
Q4 		$1.36K Buy
+38
New +$1.16K ﹤0.01% 1212

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

SJS Investment Consulting's INDV Position: Q2 2026 in Review

SJS Investment Consulting increased its Indivior Pharmaceuticals (INDV) stake by 940% in Q2 2026, buying an estimated $1.71K and bringing the position to 52 shares worth $2.13K. The position accounts for ﹤0.01% of the portfolio, ranked #1753.

SJS Investment Consulting first reported a position in INDV in Q4 2025 and has held it in 3 quarters since. 174 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • SJS Investment Consulting held 52 shares of Indivior Pharmaceuticals worth $2.13K as of Q2 2026.
  • SJS Investment Consulting bought 47 Indivior Pharmaceuticals shares in Q2 2026, an estimated $1.71K.
  • Indivior Pharmaceuticals made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1753 holding.
  • SJS Investment Consulting first reported a position in Indivior Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 174 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.